RA
SOPH icon

Royce & Associates’s SOPHiA GENETICS SOPH Stock Holding History

Royce & Associates’s Portfolio SOPH Stock Details SOPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.99M Buy
1,816,312
+1,386,055
+322% +$6.74M 0.09% 361
2025
Q4 		$2.01M Buy
+430,257
New +$1.95M 0.02% 588

Other funds holding SOPH

GIM
Generation Investment Management London, United Kingdom $11.2B AUM 0.58% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
BPC
Banque Pictet & Cie Geneva 73, Switzerland $16B AUM 29.1% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $187B AUM 18.48% 1-Year Est. Return
AWA
Alta Wealth Advisors Woburn, Massachusetts $308M AUM 27.87% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ACM
Archon Capital Management Seattle, Washington $177M AUM 108.05% 1-Year Est. Return

Royce & Associates's SOPH Position: Q1 2026 in Review

Royce & Associates increased its SOPHiA GENETICS (SOPH) stake by 322% in Q1 2026, buying an estimated $6.74M and bringing the position to 1,816,312 shares worth $8.99M. The position accounts for 0.09% of the portfolio, ranked #361.

Royce & Associates first reported a position in SOPH in Q4 2025 and has held it in 2 quarters since. 49 funds tracked by Wall St. Rank hold SOPH as of Q1 2026.

  • Royce & Associates held 1,816,312 shares of SOPHiA GENETICS worth $8.99M as of Q1 2026.
  • Royce & Associates bought 1,386,055 SOPHiA GENETICS shares in Q1 2026, an estimated $6.74M.
  • SOPHiA GENETICS made up 0.09% of Royce & Associates's portfolio in Q1 2026, its #361 holding.
  • Royce & Associates first reported a position in SOPHiA GENETICS in Q4 2025 and has held it in 2 quarters since.
  • 49 funds tracked by Wall St. Rank held SOPHiA GENETICS as of Q1 2026.

Based on Royce & Associates's 13F filing for Q1 2026, filed 12 May 2026.